Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer Clinical Trial

— ENZA-p  

Official title:

ENZA-p: A Randomised Phase II Trial Using PSMA as a Therapeutic Agent and Prognostic Indicator in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide (ANZUP 1901)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04419402
• Other study ID #: ANZUP 1901
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: August 17, 2020
• Est. completion date: January 1, 2025

Study information

• Verified date: February 2024
• Source: Australian and New Zealand Urogenital and Prostate Cancer Trials Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase 2 randomised clinical trial will investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.

Description:

This is an open label, randomised, stratified, 2-arm, multicentre phase 2 clinical trial recruiting 160 participants over 12 months and followed until 150 events occurred (approximately another 18 months). Participants will be randomised to enzalutamide or enzalutamide and Lu-PSMA in a 1:1 ratio. A minimisation approach will be used to minimise chance imbalances across the following stratification factors: study site, volume of disease (>20 versus ≤20 sites of disease measured on 68Ga-PSMA PET/CT), prior treatment with early docetaxel for castration- sensitive disease (yes vs no), and prior treatment with early abiraterone for castration-sensitive disease (yes vs no).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 162
• Est. completion date: January 1, 2025
• Est. primary completion date: July 31, 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Males aged 18 or older with metastatic adenocarcinoma of the prostate defined by:

• Documented histopathology of prostate adenocarcinoma (no features of neuroendocrine carcinoma) OR
• Metastatic disease typical of prostate cancer

2. Castration-resistant prostate cancer (defined as disease progressing despite castration by orchiectomy or ongoing luteinising hormone-releasing hormone agonist or antagonist).

3. Progressive disease with rising PSA defined by PCWG3 criteria (sequence of 2 rising values at a minimum of 1-week intervals) AND PSA = 5 ng/mL.

4. At least 2 of the following risk factors for early treatment failure with

enzalutamide:

• LDH = ULN
• ALP = ULN
• Albumin <35 g/L
• De novo metastatic disease (M1) at initial diagnosis *
• <3 years since initial diagnosis
• >5 bone metastases *
• Visceral metastases *
• PSA doubling time <84 days
• Pain requiring opiates for >14 days
• Prior treatment with abiraterone * Based on conventional imaging (CT and/or bone scan)

5. Target or non-target lesions according to RECIST 1.1

6. Significant PSMA avidity on 68Ga-PSMA PET/CT, defined as SUVmax >15 at a single site (regardless of lesion size) and SUV max >10 at sites of disease =10mm (unless subject to factors explaining a lower uptake, e.g. respiratory motion, reconstruction artefact)

7. ECOG performance status 0-2

8. Adequate renal function:

• Creatinine clearance = 40mL/ min

9. Adequate liver function:

• Bilirubin < 1.5 x upper limit of normal (ULN) (or if bilirubin is between 1.5 - 2x ULN, must have a normal conjugated bilirubin)
• AST or ALT = 2.0 x ULN (or = 5.0 x ULN in the presence of liver metastases)

10. Adequate bone marrow function:

• Platelets = 100 x109/L
• Haemoglobin = 90g/L (no red blood cell transfusion in last 4 weeks)
• Neutrophils > 1.5 x109/L

11. Estimated life expectancy > 12 weeks

12. Study treatment both planned and able to start within 21 days of randomisation

13. Willing and able to comply with all study requirements (including both treatments:

enzalutamide and Lu-PSMA), and all required study assessments

14. Signed, written, informed consent

Exclusion Criteria:

1. Prostate cancer with known significant sarcomatoid, or spindle cell, or neuroendocrine small cell components, or metastasis of other cancer to the prostate

2. 68Ga-PSMA PET/CT SUVmax < 10 at a site of measurable disease > 10mm

3. Prior treatment with enzalutamide, darolutamide, or apalutamide. Prior treatment with abiraterone is allowed.

4. Prior treatment with any PSMA-targeted radiotherapy

5. Prior chemotherapy for mCRPC. Prior docetaxel in castration-sensitive setting is permitted

6. History of another malignancy within 5 years prior to randomisation except for non-melanomatous carcinoma of the skin; or, adequately treated, non-muscle-invasive urothelial carcinoma of the bladder (i.e. Tis, Ta and low grade T1 tumours)

7. Concurrent illness, including severe infection that may jeopardise the ability of the participant to undergo the procedures outlined in this protocol with reasonable safety

8. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, including alcohol dependence or drug abuse

9. Men in sexual relationships with women of reproductive potential who are not willing/able to use medically acceptable forms of barrier contraception

10. History of:

1. seizure or any condition that may predispose to seizure (e.g. prior cortical stroke or significant brain trauma)

2. loss of consciousness or transient ischemic attack within 12 months of randomization

3. significant cardiovascular disease within the last 3 months: including myocardial infarction, unstable angina, congestive heart failure (NYHA grade II or greater, see Appendix 4), ongoing arrhythmias of Grade > 2, thromboembolic events (e.g. deep vein thrombosis, pulmonary embolism). Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed

Related Conditions & MeSH terms

• Metastatic Castration-Resistant Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Lu-PSMA
Patients will be given 7.5 GBq of Lu-PSMA in 4 doses. Dose 1 and 2 on Days 15 and 57. Doses 3 and 4 (Days 113 and 169) will be given following result of 68Ga-PSMA PET/CT at Day 92. Treatment administered every 6 weeks, x 4 cycles.
• Enzalutamide
160 mg (four 40 mg capsules) daily.

Locations

Country	Name	City	State
Australia	Royal Adelaide Hospital	Adelaide	South Australia
Australia	Royal Brisbane and Women's Hospital	Brisbane	Queensland
Australia	Chris O'Brien Lifehouse	Camperdown	New South Wales
Australia	Monash Health	Clayton	Victoria
Australia	St Vincents Hospital	Darlinghurst	New South Wales
Australia	Austin Health	Heidelberg	Victoria
Australia	St George Hospital	Kogarah	New South Wales
Australia	Liverpool Hospital	Liverpool	New South Wales
Australia	Macquarie University Hospital	Macquarie Park	New South Wales
Australia	Peter MacCallum Cancer Centre	Melbourne	Victoria
Australia	The Alfred Hospital	Melbourne	Victoria
Australia	Sir Charles Gairdner Hospital	Nedlands	Western Australia
Australia	Calvary Mater Newcastle	Newcastle	New South Wales
Australia	Fiona Stanley Hospital	Perth	Western Australia
Australia	Northern Cancer Institute	Sydney	New South Wales

Sponsors (5)

Lead Sponsor	Collaborator
Australian and New Zealand Urogenital and Prostate Cancer Trials Group	Astellas Pharma Inc, Endocyte, National Health and Medical Research Council, Clinical Trials Centre, Prostate Cancer Research Alliance

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Overall Survival	Overall survival is defined as the interval from date of randomisation to the date of death from any cause, or the date of last known follow-up alive.	Through study completion, approximately 4 years from recruitment.
Other	Resource Use and Incremental Cost-effectiveness	Information on health-care resource use will be combined with information on overall survival and quality of life to estimate the value associated with the addition of Lu-PSMA to enzalutamide in terms of the cost per Quality adjusted life year (QALY).	Through study completion, approximately 4 years from recruitment.
Other	Association between Clinical Outcomes and Imaging Analyses at Baseline and During Treatment	A variety of methods to develop, validate and compare predictive and prognostic biomarkers for both enzalutamide treatment and enzalutamide and Lu-PSMA therapy. These include but are not limited to analyses of: 1. associations of screening whole body quantitative parameters on 68Ga-PSMA PET/CT and 18F FDG PET/CT; 2. association between the change on whole body quantitative PET parameters; 3. using the 68Ga-PSMA PET/CT at Day 92, assessment of quantitative whole body PET findings will help determine the proportion of men with persistent PSMA avid disease volume in those undergoing either enzalutamide or enzalutamide and Lu-PSMA treatments; 4. a visual scoring system for both 68Ga-PSMA PET/CT and 18F FDG PET/ CT to evaluate and validate its use in treatment response; 5. QTBI (Quantitative total body imaging) heterogeneity assessment.	Through study completion, approximately 4 years from recruitment.
Other	Association between Clinical Outcomes and Possible Prognostic/Predictive Biomarkers (tissue and circulating) including CTCs and ctDNA	Translational research will include identifying tissue and circulating biomarkers that are prognostic and/or predictive of response to treatment, safety and resistance to study treatment (associations of biomarkers with clinical outcomes). These include, but are not limited to analyses of: 1. Liquid biopsies: Liquid biopsies will be collected at molecular imaging time points including at baseline, Day 92 and at first progression; 2. CTC: CTCs may be enumerated and analysed at the above time points for a variety of biomarkers.	Through to study completion, approximately 4 years from recruitment.
Primary	Prostate Specific Antigen (PSA) Progression-Free Survival	PSA progression is defined as a rise in PSA by more than or equal to 25% AND more than or equal to 2 ng/mL above the nadir (lowest PSA point). This needs to be confirmed by a repeat PSA performed at least 3 weeks later.	Date of randomisation to the date of first evidence of PSA progression - assessed up to study completion, approximately 4 years from recruitment.
Secondary	Radiographic Progression-Free Survival	Radiographic progression-free survival is defined as the interval from the date of randomisation to the date of first evidence of radiographic progression on imaging, or the date of last known follow-up without progression.	Date of randomisation to the date of first evidence of radiographic progression on imaging. Assessed every 12 weeks through study completion, approximately 4 years from start of recruitment.
Secondary	Prostate Specific Antigen (PSA) response rate	PSA response rate is defined as the proportion of participants in each group with a PSA reduction of 50% or more from baseline.	Date of randomisation through study completion, approximately 4 years from start of recruitment. Early rises in PSA prior to 12 weeks will be disregarded in determining PSA response
Secondary	Pain response and Progression-Free Survival	Pain is measured using the McGill-Melzack Present Pain Intensity scale (PPI). Pain Response is defined as a reduction of 2 or more points for participants with a baseline PPI score of 2 or more. Pain progression is defined as and an increase of 1 or more points in the nadir PPI score.; Pain Response is defined as a reduction of 2 or more points for participants with a baseline PPI score of 2 or more.; Pain progression is defined as and an increase of 1 or more points in the nadir PPI score.	Date of randomisation through study completion, approximately 4 years from start of recruitment
Secondary	Clinical Progression-Free Survival	Clinical progression is defined by progression on imaging, development of symptoms attributable to cancer progression, the need for radiotherapy to new metastases or initiation of other anticancer treatment for prostate cancer.	Date of randomisation to the date of first clinical evidence of disease progression or death from any cause. Assessed up to study completion approximately 4 years from recruitment.
Secondary	Aspects of Health-related Quality of life (HRQL)	The European Organisation for Research and Treatment of Cancer (EORTC) core quality of life questionnaire includes five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), and a global health and quality-of-life scale to assess HRQL in cancer patients. The Patient DATA form is a simple, multi-item quality of life instrument based on 11-point numeric rating scales for a range of relevant symptoms and functions. It combines cancer specific items from the UBQ-C, GLQ-8 and LASA cancer-specific quality of life instruments. The Fear of Cancer Progression form is a short questionnaire assessing possible future concerns related to the participant's illness.	Assessed every 4-6 weeks, through study completion, approximately 4 years from recruitment.
Secondary	Frequency and Severity of Adverse Events	The Common Terminology Criteria for Adverse Events (CTCAE) v5.0 will be used to classify and grade the intensity of adverse events during study treatment.	Through study completion, approximately 4 years from recruitment.

External Links

•   Description: Sponsor's website